Abatacept for Treatment of Recurrent or de Novo Autoimmune Hepatitis

Summary

The purpose of this study is to evaluate whether Orencia® (Abatacept) improves outcomes in liver transplant patients with recurrent or de novo AIH (autoimmune hepatitis) that has not responded to previous therapy. AIH that does not respond to steroids or conventional immunotherapy often affects young patients and leads to irreversible liver damage. There is currently no effective therapy for this condition.

Timeline

Start

2020-03-09

Primary completion

2020-07-23

Completion

2020-07-23

Drugs

Indications